221
Participants
Start Date
September 14, 2020
Primary Completion Date
September 30, 2026
Study Completion Date
December 31, 2030
Chemoradiation
Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
Lancaster General Hospital, Lancaster
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Chester County Hospital, West Chester
University of Alabama, Birmingham
Washington University School of Medicine, St Louis
Montefiore Medical Center, The Bronx
The Brigham and Women's Hospital, Boston
Rutger's University / Cancer Institute of New Jersey, New Brunswick
Abramson Cancer Center at Penn Medicine
OTHER